Abstract 1730P
Background
We hypothesized that PARP inhibitor Fluzoparib and preoperative radiotherapy (RT) will transform inoperable or borderline operable soft tissue sarcoma (STS) into an operable disease without increase of major wound complications (MWCs).
Methods
Primary or recurrent non-metastatic unresectable or borderline resectable extremity or trunk STS was enrolled. Patients received preoperative moderately fractionated RT of 43.5Gy in 15 fractions with concurrent and sequential Fluzoparib (100mg Bid for 10 weeks in total), followed by wide resection. NCI-CTC 5.0, RECIST 1.1 criteria, and EORTC-STBSG criteria was used to evaluate acute toxicities, clinical and pathological response. The primary endpoint was defined as MWCs as per the SR2 criteria within 4 months post-surgery.
Results
From Jun 2023 to Apr 2024, 49 patients were enrolled and 46 completed RT. Forty-six tumours (93.9%) were evaluated as unresectable or borderline resectable, with 40 tumor (81.6%) adjacent to or encircling key structures. There were 40, 6 and 3 patients having full-dose Fluzoparib, drug dose reduction and RT alone, respectively. The observed ≥Grade 3 Fluzoparib-related or RT-related acute toxicity is anemia in 1 patient, and skin reaction in two patients. There're 8 (8/43, 18.6%), 11 (25.6%) and 24 patients (55.8%) who achieved PR, tumor reduction by 20% and SD as per RECIST 1.1 at 4-6 weeks post-radiotherapy, respectively. Till May, 2024, there were 40 patients who underwent non-R2 limb-conserving surgery, with 26 R0 and 14 R1 resection (margin less than 1mm). Thirteen out of 37 patients (35.1%) with at least 6 weeks follow-up had MWCs, with 12 in lower extremity (12/33, 36.4%). As per the EORTC criteria, there were 1 (1/38, 2.6%), 7 (18.4%) and 10 (26.3%) patients achieving pathological Grade B, C, and D remission. In all, 28 patients (73.7%) had higher than 10% of hyalinization/fibrosis.
Conclusions
For patients with non-metastatic extremity or trunk STS, the combination of PARP inhibitor and pre-operative moderately fractionated RT is safe and well-tolerated, and make majority of tumors transformed into operable disease.
Clinical trial identification
NCT05938374.
Editorial acknowledgement
Funding
CAMS Innovation Fund for Medical Sciences (CIFMS) [grant number 2023-I2M-C&T-B-089] and the Beijing Hope Run Special Fund of Cancer Foundation of China [grant number LC2020A15].
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1741P - Ethically-sensitive clinical scenarios in adult patients with sarcomas: A real-world single-institution survey and a classification attempt
Presenter: Paolo G. Casali
Session: Poster session 06
1742P - Factors influencing awareness of patient associations in sarcoma: A multicentric cross-sectional study
Presenter: Pau Mascaró Baselga
Session: Poster session 06
1743P - A phase II study of fruquintinib in the 1L or 2L treatment of unresectable metastatic soft tissue sarcoma
Presenter: Zhiguo Luo
Session: Poster session 06
1745P - How to optimize the response with trabectedin in soft tissue sarcomas? Data from a high-volume center
Presenter: Sebastian Diaz
Session: Poster session 06
1746P - Real-world characterization of patients with advanced or metastatic dedifferentiated liposarcoma (DDLPS) in Japan in MASTER KEY project
Presenter: Kenji Tsuchihashi
Session: Poster session 06
1747P - Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study
Presenter: Evelyne Roets
Session: Poster session 06
1748P - A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)
Presenter: Xi Guo
Session: Poster session 06
1749P - Vertebral MRI in the screening for bone metastasis in myxoid liposarcoma: Is it justified?
Presenter: Tania Moussa
Session: Poster session 06
1750P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Gale Rizzae Mercado Alcala
Session: Poster session 06
1751P - Clinical and survival data of 336 myxoid liposarcoma patients: The Gustave Roussy experience
Presenter: Tarek Assi
Session: Poster session 06